Pyrrolobenzimidazoles in cancer treatment

Bibliography

• STRUCK RF: Nitrogen mustard and related structures.In: Cancer Chemotherapeutic Agents. Foyle WO (Ed.), American Chemical Society, Washington, DC (1995) 112–120.
   Google Scholar
• ELLIOTT RD: Nitrosoureas. In: Cancer ChemotherapeuticAgents. Foyle WO (Ed.), American Chemical Society, Wash-ington, DC (1995) 134–143.
   Google Scholar
• REYNOLDS RC: Aziridines. In: Cancer ChemotherapeuticAgents. Foyle WO (Ed.), American Chemical Society, Wash-ington, DC (1995) 187–197.
   Google Scholar
• SRINIVASAN AR, OLSON WK: Molecular models of nu-cleic acid triple helixes. I. DNA and RNA backbone complexes. J. Am. Chem. Soc. (1998) 120(3):484–491.
   Google Scholar
• PAULL DK, SHOEMAKER RH, HODES L et al.: Display and analysis of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst. (1989) 81:1088–1092.
   PubMed Web of Science ®Google Scholar
• ••Describes the use of the COMPARE algorithm in elucidatingcancer drug mechanism from differential activity.
   Google Scholar
• TRAXLER PM: Protein tyrosine kinase inhibitors in can- cer treatment. Exp. Opin. Ther. Patents (1997) 7(6):571–588.
   Web of Science ®Google Scholar
• CRAIG A, VANSTONE D, AGRAWAL S: Patent strategies in the antisense oligonucleotide based therapeutic ap-proach. Exp. Opin. Ther. Patents (1997) 7 (10) :1175–1182.
   Web of Science ®Google Scholar
• VAN CUTSEM E: A glimpse of the future. New directions in the treatment of colorectal cancer. Eur. J. Cancer (1996) 32A:S23–S27.
   Google Scholar
• GIOVANELLA BC: Topoisomerase I inhibitors. In: Can-cer Therapeutics. Teicher BA (Ed.), Humana Press, Inc., To-towa (1997) 137–152.
   Google Scholar
• •A current review of topoisomerase I inhibitors that discusses well-established agents.
   Google Scholar
• POMMIER Y: DNA topoisomerase II inhibitors. In: Can- cer Therapeutics. Teicher BA (Ed.), Humana Press, Inc., To-towa (1997) :153–174.
   Google Scholar
• •A current review of topoisomerase II inhibitors that dis-cusses well-established agents.
   Google Scholar
• SKIBO ES, GORDON S, BESS L, BORUAH R, HEILEMAN J: Studies of pyrrolo [1,2-a]benzimidazole quinone DT-diaphorase substrate activity, topoisomerase II inhibi-tion activity, and DNA Reductive alkylation. J. Med. Chem. (1997) 40:1327–1339.
   Google Scholar
• SKIBO EB: The discovery of the pyrrolo [1, 2-a]benzimi-dazole antitumor agents - the design of selective antitu-mor agents. Curr. Med. Chem. (1996) 2:900–931.
   Google Scholar
• ••An earlier review on the pyrrolobenzimidazoles; discusseschemistry and structure-activity relationships.
   Google Scholar
• KIM HS, YU M, JAING Q, LEBRETON PR: UV photoelec-tron and Ab Initio quantum mechanical characteriza-tion of 2'-deoxyguanosine 5'-phosphate: electronic influences on DNA alkylation patterns. J. Am. Chem. Soc. (1993) 115:6169–6183.
   Web of Science ®Google Scholar
• MAYALARP SP, HARGREAVES RHJ, BUTLER J, O'HARE CC, HARTLEY JA: Crosslinking and sequence specific alky-lation of DNA by aziridinylquinones. 1. Quinone me-thides. J. Med. Chem. (1996) 39:531–537.
   Google Scholar
• LEE C-S, PFEIFER GP, GIBSON NW: Mapping of DNA alky-lation sites induced by aziridinylbenzoquinones in hu-man cells by ligation-mediated polymerase chain reaction. Cancer Res. (1994) 54:1622–1626.
   Google Scholar
• LUSTHOF KJ, DE MOL NJ, JANSSEN LHM, VERBOOM W, REINHOUDT DN: DNA alkylation and formation of DNA interstrand cross-links by potential antitumour 2,5-bis(1-aziridiny1)-1,4-benzoquinones. Chem. Biol. Interact. (1989) 70:249–262.
   PubMed Web of Science ®Google Scholar
• GUPTA RC, GARG A, EARLEY K, AGARWAL SC, LAMBERT GR, NESNOW S: DNA adducts of the antitumor agent diaziquone. Cancer Res. (1991) 51:5198–5204.
   Google Scholar
• GOLDING BT, BLEASDALE C, MCGINNIS J et al: The mechanism of decomposition of N-methyl-N-nitrosourea (MNU) in water and a study of its reactions with 2'-deoxyguanosine, 2'-deoxyguanosine 5'-mon-ophosphate and d(GTGCAC). Tetrahedron (1997) 53(104063–4082.
   Google Scholar
• •This article provides evidence that the phosphate backbone is the main target of this important class of antitumour. Likewise, the phosphate backbone is the main target of the pyrrlobenzimidazoles.
   Google Scholar
• RINK SM, SOLOMON MS, TAYLOR MJ, RAJUR SB, MCLAUGHLIN LW, HOPKINS PB: Colvent structure of a nitrogen mustard-induced DNA interstrand cross-link: an N7 to N7 linkage of deoxyguansine residues at the duplex sequence 5'-d(GNC). J. Am. Chem. Soc. (1993) 115:2551–2557.
   Web of Science ®Google Scholar
• CONRAD J, MULLER N, EISENBRAND G: Studies on thestability of trialkyl phosphates and di-(2'-d-eoxythymine) phosphotriesters in alkyline and neu-tral solution. A model study for hydrolysis of phosphotriesters in DNA and on the influence of a 13-hydroxyethyl ester group. Chem. Biol. Interact. (1986) 60:57–65.
   Google Scholar
• BANNON P, VERLEY W: Alkylation of phosphates and stability of phosphate triesters in DNA. Eur. J. Biochem. (1972) 31:103–111.
   PubMedGoogle Scholar
• SWENSEN DH, LAWLEY PD: Alkylation of deoxyribonu-cleic acid by carcinogens dimethyl sulfate, ethyl methanesulfonate, N-ethyl-N-nitrosourea. Biochem. I (1978) 171:575–587.
   Google Scholar
• HEMMINKI A, VAYRYNEN T, HEMMINKI K: Reaction ki-netics of alkyl epoxides with DNA and other nucleo-philes. Chem. Biol. Interact. (1994) 93:51–58.
   Google Scholar
• YATES JM, FENNELL TR, TURNER MJ, RECIO L, SUMMER SCJ: Characterization of phosphodiester adducts pro-duced by the reacton of cyanoethylene oxide with nu-cleotides. Carcinogenesis (1994) 15:277–283.
   PubMed Web of Science ®Google Scholar
• BOYER MJ: Bioreductive agents: a clinical update. On-col. Res. (1997) 9(6-7):391–395.
   Google Scholar
• •A recent review of the reductive activation of drugs in cancer cells.
   Google Scholar
• RILEY RJ, WORKMAN P: DT-diaphorase and cancer che-motherapy. Biochem. Pharm. (1992) 43:1657–1669.
   PubMed Web of Science ®Google Scholar
• RAUTH AM, GOLDBERG Z, MISRA V: DT-diaphorase: possible roles in cancer chemotherapy and carcino-genesis. Oncol Res. (1997) 9(6-7):339–349.
   Google Scholar
• •A recent review of DT-diaphorase, an enzyme important in the reductive activation process.
   Google Scholar
• WU KB, KNOX R, SUN XZ et al.: Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQ02), a dihy-dronicotinamide riboside dependent oxidoreductase. Arch. Biochem. Biophys. (1997) 347(2):221–228.
   PubMed Web of Science ®Google Scholar
• KELSEY KT, ROSS D, TRAVER RD et al.: Ethnic variation in the prevalence of a common NAD(P)H quinone oxi-doreductase polymorphism and its implications for anti-cancer chemotherapy. Br. J. Cancer (1997) 76(7):852–854.
   PubMed Web of Science ®Google Scholar
• •Discusses DT-diaphorase polymorphism, implies the exis-tance of variation in the enzyme among cancer types.
   Google Scholar
• CUMMINGS J, SPANSWICK VJ, GARDINER J, RITCHIE A, SMYTH JF: Pharmacological and biochemical determi-nants of the antitumour activity of the indoloquinone E09. Biochem. Pharmacol (1998) 55 (3):253–260.
   Google Scholar
• LIU LF: Topoisomerase poisons as antitumor drugs.Ann. Rev. Biochem. (1989) 58:351–375.
   PubMed Web of Science ®Google Scholar
• MCLEOD HL, DOUGLAS F, OATES M et al: Topoi-somerase land II activity in human breast, cervix, lung and colon cancer. Int. J. Cancer (1994) 59:607–611.
   PubMed Web of Science ®Google Scholar
• MENTA E, PALUMBO M: Novel antineoplastic agents. Exp. Opin. Ther. Patents (1997) 7 (12) :1401–1426.
   Web of Science ®Google Scholar
• ••A recent review of cancer chemotherapeutic agent patentstrategies; discusses novel targets of cancer chemotheropeu-tic agents including topoisomerase I and II.
   Google Scholar
• DARPA P: Determinants of cellular sensitivity to topoisomerase-targeting antitumor drugs. Adv. Phar-macol. (1994) 29B:127–143.
   Google Scholar
• SANCAR A: DNA excision repair. Ann. Rev. Biochem. (1996) 65:43–71.
   PubMed Web of Science ®Google Scholar
• SKIBO EB, SCHULZ WG: Pyrrolo[1,2-a]benzimidazole-based aziridinyl quinones. a new class of DNA cleaving agent exhibiting G and A base specificity. J. Med. Chem. (1993) 36:3050–3055.
   Google Scholar
• •First report of the mechanism of the pyrrolobenzimidazole antitumour agents.
   Google Scholar
• SCHULZ WG, NIEMAN RA, SKIBO EB: Evidence for DNA phosphate backbone alkylation and cleavage by pyr-rolo [1,2-.9] benzimidazoles, small molecules capable of causing sequence specific phosphodiester bond hy-drolysis. Proc. Natl. Acad. Sci. USA (1995) 92:11854–11858.
   Google Scholar
• SIGMAN DS: Chemical nucleases. Biochemistry (1990) 29:9097–9105.
   PubMed Web of Science ®Google Scholar
• GOLDBERG IH: Mechanism of neocarzinostatin action: role of DNA microstructure in determination of chem-istry of bistranded oxidative damage. Acc. Chem. Res. (1991) 24:191–198.
   Web of Science ®Google Scholar
• NICOLAOU KC, DAI W-M: Chemistry and biology of the enediyne anticancer antibiotics. Angew Chem. Int. Ed. Engl. (1991) 30:1387–1350.
   Web of Science ®Google Scholar
• JUBIAN V, DIXON RP, HAMILTON AD: Molecular recog-nition and catalysis. acceleration of phosphodiester cleavage by a simple hydrogen-bonding receptor. J. Am. Chem. Soc. (1992) 114:1120–1121.
   Google Scholar
• SCHULZ WG, ISLAM E, SKIBO EB: Pyrrolo [1,2-a]benzimidazole-based quinones and iminoqui-nones, the role of the 3-substituent on cytotoxicity. J. Merl. Chem. (1995) 38:109–118.
   PubMed Web of Science ®Google Scholar
• FRANCK RW, TOMASZ M: The chemistry of mitomycins. In: The Chemistry of Antitumour Agents. Wilman DE (Ed.), Blackie & Sons Ltd., Glasgow, UK (1990) 379–394.
   Google Scholar
• BAILEY SM, WYATT MD, FRIEDLOS F et al.: Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent E09. Br. J. Cancer (1997) 76 (12):1596–1603.
   Google Scholar
• HARGREAVES RHJ, MAYALARP SP, BUTLER J, MCADAM SR, OHARE CC, HARTLEY JA: Cross-linking and se-quence specific alkylation of DNA by aziridinyl qui-nones. 2. Structure requirements for sequence selectivity. J. Merl. Chem. (1997) 40 (3) :357–361.
   Google Scholar
• MAXAM AM, GILBERT W: Sequencing end-labeled DNA with base-specific chemical cleavages. Meth. Enzymol. (1980) 65:499–560.
   PubMedGoogle Scholar
• SKIBO EB, ISLAM I, SCHULZ WG, ZHOU R, BESS L, BO-RUAH R: The organic chemistry of the pyrrolo [1,2-a]benzimidazole antitumor agents. An example of rational drug design. Synlett (1996) 4:297–309.
   Google Scholar
• ISLAM I, SKIBO EB: Synthesis and physical studies of azamitosene and iminoazamitosene reductive alky-lating agents. Iminoquinone hydrolytic stability, syn/anti isomerization, and electrochemistry. J. Org. Chem. (1990) 55:3195–3205.
   Google Scholar
• •First description of the synthesis of the pyrrolobenzimidazoles.
   Google Scholar
• ISLAM I, SKIBO EB, DORR RT, ALBERTS DS: Structure- studies of antitumor agents based on pyrrolo [1,2-a]benzimidazoles: new reductive alkylating DNA cleaving agents. J. Med. Chem. (1991) 34:2954–2961.
   PubMed Web of Science ®Google Scholar
• •First description of the cancer chemotherapeutic value of the pyrrolobenzimidazoles.
   Google Scholar
• SKIBO EB, ISLAM I, HEILEMAN MJ, SCHULZ WG: Structure-activity studies of benzimidazole-based DNA-cleaving agents. comparison of benzimidazole, pyrrolobenzimidazole and tetrahydropyridobenzimi-dazole analogues. J. Med. Chem. (1994) 37:78–92.
   Google Scholar
• BORUAH RC, SKIBO EB: A comparison of the cytotoxic and physical properties of aziridinyl quinone deriva-tives based on the pyrrolo [1,2- a]benzimidazole and pyrrolo [1,2-a]indole ring systems. J. Med. Chem. (1994) 37:1625–1631.
   PubMed Web of Science ®Google Scholar
• ZHOU R, SKIBO EB: Chemistry of the pyrrolo[1,2-a]benzimidazole antitumor agents: influence of the 7-substituent on the ability to alkylate DNA and in-hibit topoisomerase II. J. Merl. Chem. (1996) 39:4321–4331.
   Google Scholar
• JACKSON RC, SEBOLT JS, SCHILLIS JL, LEOPOLD WR: The pyrazoloacridines: approaches to the development of a carcinoma-selective cytotoxic agent. Cancer Invest. (1990) 8:39–47.
   PubMed Web of Science ®Google Scholar
• BOWDEN GT, GARCIA D, PENG Y-M, ALBERTS DS: Mo-lecular pharmacology of the anthracycline drug 9,10-anthracenedicarboxaldehyde bis [(4,5-dihydro-lh -imidazol-2-yl)hydrazone] dihydrochloride. Cancer Res. (1982) 42:2660–2665.
   PubMed Web of Science ®Google Scholar
• ABDELLA BRJ, FISHER JA: Chemical perspective on the anthracycline antitumor antibiotics. J. Environ. Health Perspect. (1985) 64:3–18.
   Google Scholar
• HORTOBAGYI GN: Anthracyclines in the treatment of cancer: an overview. Drugs (1997) 54:1–7.
   PubMed Web of Science ®Google Scholar
• •An excellent short review of the anthracyclines.
   Google Scholar
• MALONNE H, ATASSI G: DNA topoisomerase targeting drugs: mechanisms of action and perspectives. Anti Cancer Drug (1997) 8(9):811–822.
   PubMed Web of Science ®Google Scholar
• •An excellent overview of the utility of targeting topoi-somerases for cancer chemotherapeutic agent design.
   Google Scholar
• SUFFNESS M, DOUROS J: Micellaneous natural products with anticancer activity. In: Anticancer Agents Based on Natural Product Models. Academic Press, Inc., New York (1980) 465–487.
   Google Scholar
• HOLDEN JA, ROLFSON DH, WITTWER CT: Human DNA topoisomerase II: evaluation of enzyme activity in
   Google Scholar
• •This article provides the rationale for targeting topoi-somerase II in cancer chemotherapeutic agent design.
   Google Scholar
• ESTEY D, SILBERMAN LA-H: m-AMSA-Induced DNA strand breaks: a potential measure of the malignant phenotype. Proc. Am. Assoc. Cancer Res. (1985) 26:227.
   Google Scholar
• POMMIER Y, SCHWARTZ RE, KOHN KW, ZWELLING LA:Formation and rejoining of deoxyribonucleic acid double- stranded breaks induced in isolated nuclei by antineoplastic intercalating agents. Biochemistry (1984) 23:3194–3201.
   Google Scholar
• ROSS W, ROWE T, GLISSON F, YALOWICH J, SIU L: Role oftopoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res. (1984) 44:5857–5860.
   PubMed Web of Science ®Google Scholar
• FUJII N, YAMASHITA Y, ARIMA Y, NAGASHIMA M, NAKANO H: Induction of topoisomerase II-mediated DNA cleavage by the plant naphthoquinones plum-bagin and shikonin. Antimicrob. Agents. Chem other. (1992) 36:2589–2594.
   PubMed Web of Science ®Google Scholar
• PERMANA PA, SNAPKA RM, SHEN LL, CHU DTW, CLEM-ENT JJ, PLATTNER JJ: Quinobenoxazines: a class of novel antitumor quinolones and potent mammalian DNA topoisomerase II catalytic inhibitors. Biochemistry (1994) 33:11333–11339.
   PubMed Web of Science ®Google Scholar
• DRAKE FH, HOFMANN GA, MONG SM et al.: In vitro andintracellular inhibition of topoisomerase II by the an-titumor agent mebarone. Cancer Res. (1989) 49:2578–2583.
   PubMed Web of Science ®Google Scholar
• ISHIDA R, MIKI T, NARITA T et al.: Inhibition of intracel-lular topoisomerase II by antitumor (2,6-dioxopiperazine) derivatives : mode of cell growth in-hibition distinct from that of cleavable complex -for-ming type inhibitors. Cancer Res. (1991) 51:4909–4916.
   PubMed Web of Science ®Google Scholar
• WILSON WD, JONES RL: Intercalating drugs: DNA bind-ing and molecular pharmacology. Adv. Pharmacol. Che-mother. (1981) 18:177–222.
   PubMedGoogle Scholar
• CHENG CC, ZEE-CHENG RKY: The design, synthesis and development of a new class of potential antineoplastic anthraquinones. In: Progress in Medicinal Chemistry. Ellis GP, West GB (Eds.), Elsevier, Amsterdam, The Netherlands (1983) 83–118.
   Google Scholar
• CHOLODY WM, HERNANDEZ L, HASSNER L, SCUDIERO DA, DJURICKOVIC DB, MICHEJDA CJ: Bisimidazoacrido-nes and related compounds: new antineoplastic agents with high selectivity against colon tumors. J. Med. Chem. (1995) 38:3043–3052.
   PubMed Web of Science ®Google Scholar
• CHOLODY WM, MARTELLI S, KONOPA J: Chromophore-modified antineoplastic imidazoacridones. synthesis and activity against murine leukemias. J. Med. Chem. (1992) 35:378–382.
   Google Scholar
• ANTONINI I, COLA D, POLUCCI P, BONTEMPS-GRACZ M,BOROWSKI E, MARTELLI S: Synthesis of (dial-kylamino) alkyl-disubstituted pyrimido [5, 6,1-de lacridines, a novel group of anticancer agents active on a multidrug resistant cell lines. J. Med. Chem. (1995) 38:3282–3286.
   Google Scholar
• LETEURTRE F, KOHLHAGEN G, PAULL KD, POMMIER Y:Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the national cancer institute preclinical antitumor drug discovery screen. J. Natl. Cancer Inst. (1994) 86:1239–1244.
   Google Scholar
• RADISKY DC, RADISKY ES, BARROWS LR, COPP BR, KRA-MER RA, IRELAND CM: Novel cytotoxic topoisomerase II inhibiting pyrroloiminoquinones from Fijian sponges of the genus Zyzzya. J. Am. Chem. Soc. (1993) 115:1632–1638.
   Web of Science ®Google Scholar
• AMATORE C, ANNE A, FLORENT JC, MOIROUX J: Mecha-nism of the electrochemical reduction of hydroxyimi-noanthraquinones in DMF. J. Electroanal Chem. (1986) 207:151–160.
   Google Scholar
• CORBETT AH, GUERRY P, PFLIEGER P, OSHEROFF N: Apyrimido [1,6-a]benzimidazole that enhances DNA cleavage mediated by eukaryotic topoisomerase II: a novel class of topoisomerase II-targeted drugs with cy-totoxic potential. Antimicrob. Agents Chemother. (1993) 37:2599–2605.
   PubMed Web of Science ®Google Scholar
• BRANA MF, CASTELLANO JM, KEILHAUER G et al: Ben-zimidazo [1,2-c]quinazolines: a new class of antitumor compounds. Anti-Cancer Drug Des. (1994) 9:527–538.
   PubMedGoogle Scholar
• OKA H, YOSHINARI T, MURAI T et al.: A new topoi-somerase II inhibitor, BE-10988, produced by a Strep-tomycete. I. Taxonomy, fermentation, isolation, and characterization. J Antibiot (1991) 44:486–491.
   Google Scholar
• MOODY CJ, ROFFEY JRA, STEPHENS MA, STRATFORD IJ: Synthesis and cytotoxic activity of indolyl thiazoles. Anti-Cancer Drug (1997) 8 (5) 489–499.
   Google Scholar
• RIOU JF, HELISSEY P, GRONDARD L, GIORGI-RENAULT S: Inhibition of eukaryotic DNA topoisomerase I and II activities by indoloquinolinedione derivatives. Mol Pharmacol. (1991) 40:699–706.
   PubMed Web of Science ®Google Scholar
• SKIBO EB, GILCHRIST JH: Synthesis and electrochemis-try of pyrimidoquinazoline-5, 10- diones. Design of hydrolytically stable high potential quinones and new reductive alkylation systems. J. Org. Chem. (1988) 53:4209–4218.
   Google Scholar
• LEMUS RL, SKIBO EB: Design of pyrimido [4,5-g] quinazoline-based anthraquinone mimics. Structure-activity relationship for quinone methide formation and the influence of internal hydrogen bonds on qui-none methide fate. J. Org. Chem. (1992) 57:5649–5660.
   Google Scholar
• VIVASMEJIA PE, COX 0, GONZALEZ FA: Inhibition of hu-man topoisomerase II by antineoplastic benzazolo [3,2-a]quinolinium chlorides. Mol. Cell. Biochem. (1998) 178:203–212.
   Google Scholar